Jackson Square Partners LLC Has $20.28 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Jackson Square Partners LLC reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 16.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,045 shares of the company’s stock after selling 12,215 shares during the period. Medpace makes up approximately 2.2% of Jackson Square Partners LLC’s holdings, making the stock its 22nd largest holding. Jackson Square Partners LLC owned approximately 0.20% of Medpace worth $20,281,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Centaurus Financial Inc. lifted its holdings in Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after buying an additional 29 shares in the last quarter. Lindbrook Capital LLC grew its position in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after buying an additional 29 shares during the period. HBK Sorce Advisory LLC lifted its stake in shares of Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after purchasing an additional 29 shares during the period. Assetmark Inc. boosted its stake in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after acquiring an additional 29 shares during the last quarter. Finally, Proficio Capital Partners LLC grew its holdings in shares of Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after buying an additional 29 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

Shares of MEDP opened at $330.59 on Tuesday. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The firm has a market cap of $10.07 billion, a P/E ratio of 26.17, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The firm’s 50-day simple moving average is $337.29 and its 200 day simple moving average is $339.65.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Leerink Partners initiated coverage on Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 price target for the company. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research note on Monday. Finally, Robert W. Baird increased their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.